These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24768678)

  • 1. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.
    Butz BK; Wen T; Gleich GJ; Furuta GT; Spergel J; King E; Kramer RE; Collins MH; Stucke E; Mangeot C; Jackson WD; O'Gorman M; Abonia JP; Pentiuk S; Putnam PE; Rothenberg ME
    Gastroenterology; 2014 Aug; 147(2):324-33.e5. PubMed ID: 24768678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis.
    Alexander JA; Jung KW; Arora AS; Enders F; Katzka DA; Kephardt GM; Kita H; Kryzer LA; Romero Y; Smyrk TC; Talley NJ
    Clin Gastroenterol Hepatol; 2012 Jul; 10(7):742-749.e1. PubMed ID: 22475741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children With Eosinophilic Esophagitis.
    Fable JM; Fernandez M; Goodine S; Lerer T; Sayej WN
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):26-32. PubMed ID: 28489670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
    Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
    Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.
    Konikoff MR; Noel RJ; Blanchard C; Kirby C; Jameson SC; Buckmeier BK; Akers R; Cohen MB; Collins MH; Assa'ad AH; Aceves SS; Putnam PE; Rothenberg ME
    Gastroenterology; 2006 Nov; 131(5):1381-91. PubMed ID: 17101314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia.
    Moawad FJ; Veerappan GR; Dias JA; Baker TP; Maydonovitch CL; Wong RK
    Am J Gastroenterol; 2013 Mar; 108(3):366-72. PubMed ID: 23399553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
    Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis.
    Lucendo AJ; De Rezende LC; Jiménez-Contreras S; Yagüe-Compadre JL; González-Cervera J; Mota-Huertas T; Guagnozzi D; Angueira T; González-Castillo S; Arias A
    Dig Dis Sci; 2011 Dec; 56(12):3551-8. PubMed ID: 21674173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
    Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
    Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Gupta SK; Lan L; Williams J; Hirano I
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):666-673.e8. PubMed ID: 29902649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis.
    Peterson KA; Thomas KL; Hilden K; Emerson LL; Wills JC; Fang JC
    Dig Dis Sci; 2010 May; 55(5):1313-9. PubMed ID: 19533356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
    Gupta SK; Vitanza JM; Collins MH
    Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials.
    Murali AR; Gupta A; Attar BM; Ravi V; Koduru P
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1111-9. PubMed ID: 26699695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
    Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
    Hirano I; Safroneeva E; Roumet MC; Comer GM; Eagle G; Schoepfer A; Falk GW
    Aliment Pharmacol Ther; 2020 Apr; 51(8):750-759. PubMed ID: 32149424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
    Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma.
    Westbroek J; Saarelainen S; Laher M; O'Brien J; Barnacle H; Efthimiou J
    Respir Med; 1999 Oct; 93(10):689-99. PubMed ID: 10581657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis.
    Schoepfer AM; Hirano I; Coslovsky M; Roumet MC; Zwahlen M; Kuehni CE; Hafner D; Alexander JA; Dellon ES; Gonsalves N; Leung J; Bussmann C; Collins MH; Newbury RO; Smyrk TC; Woosley JT; Yang GY; Romero Y; Katzka DA; Furuta GT; Gupta SK; Aceves SS; Chehade M; Spergel JM; Falk GW; Meltzer BA; Comer GM; Straumann A; Safroneeva E;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1477-1488.e10. PubMed ID: 30476587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.